Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients

REFERENCES

• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295.
   PubMed Web of Science ®Google Scholar
• Vanhove GF, Schapiro JM, Winters MA, et al. Patient com-pliance and drug failure in protease inhibitor monotherapy [letter]. JAMA. 1996;276:1955–1956.
   PubMed Web of Science ®Google Scholar
• Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitor monotherapy. Nature. 1995;374:569–571.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Anton P, Gonzalez-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS. 1998;12:1112–1113.
   PubMed Web of Science ®Google Scholar
• Singh N, Berman S, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824–830.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response: California Collabora-tive Treatment Group. AIDS. 1999;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic out-comes for human immunodeficiency virus-infected per-sons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366.
   PubMed Web of Science ®Google Scholar
• Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO Cohort. J Acquir Im-mune Defic Syndr. 2001;28:232–239.
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic moni-toring. Clin Infect Dis. 2001;33:1417–1423.
   PubMed Web of Science ®Google Scholar
• Duong M, Piroth L, Grappin M, et al. Evaluation of the patient medication adherence questionnaire as a tool for self-reported adherence assessment in HIV-infected pa-tients on antiretroviral regimens. HIV Clin Trials. 2001;2(2)128–135.
   Google Scholar
• Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43–49.
   PubMedGoogle Scholar
• Von Korff M, Gruman J, Schaefer J, Curry SJ, Wagner EH. Collaborative management of chronic illness. Ann Intern Med. 1997;127:1097–1102.
   PubMed Web of Science ®Google Scholar
• Greenberg RN. Overview of patient compliance with medi-cation dosing: a literature review. Clin Ther. 1984;6:592–599.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Clague H, et al. Provider as-sessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435–442.
   PubMed Web of Science ®Google Scholar
• Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360.
   PubMed Web of Science ®Google Scholar
• Kastrissios H, Suarez J-R, Katzenstein D, et al. Character-izing patterns of drug-taking behaviour with a multiple drug regimen in an AIDS clinical trial. AIDS. 1998;12:2295–2303.
   PubMed Web of Science ®Google Scholar
• d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reason for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-NaIve Patients. AIDS. 2000;14:499-507.
   PubMed Web of Science ®Google Scholar
• Le Moing V, Chene G, Leport C, et al. Impact of discontinu-ation of initial protease inhibitor therapy on further virologic response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis. 2001;34:239–247.
   PubMed Web of Science ®Google Scholar
• Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000,30\(suppl 2):S171–176.
   PubMed Web of Science ®Google Scholar
• Chesney MA, Ickovics JR, Chambers DB, et al. Self-re-ported adherence to antiretroviral medications among par-ticipants in HIV clinical trials: the AACTG adherence instru-ments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clini-cal Trials Group (AACTG). AIDS Care. 2000;12:255–266.
   PubMed Web of Science ®Google Scholar
• Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Im-mune Defic Syndr. 2000;23:386–395.
   PubMed Web of Science ®Google Scholar
• Wilson IB, Tchetgen E, Spiegelman D. Patterns of adher-ence with antiretroviral medication: an examination of be-tween-medication differences. J Acquir Immune Defic Syndr. 2001;28:259–263.
   PubMed Web of Science ®Google Scholar
• Gordillo V, del Amo J, Soriano V, Gonzales-Lahoz J. Sociodemographic and psychological variables influenc-ing adherence to antiretroviral therapy. AIDS. 1999;13:1763–1769.
   PubMed Web of Science ®Google Scholar
• Clumeck N, Goebel F, Rozembaum W, et al. Simplification with abacavir based-regimen triple nucleoside therapy ver-sus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1 infected patients with unde-tectable plasma HIV-1 RNA. AIDS. 200115: 1517–1526.
   Google Scholar
• Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIVCIin Thais. 2000;1(1):36–49.
   PubMedGoogle Scholar
• Melbourne K, Geletko S, Brown S, et al. Electronic adher-ence assessment versus self-report in HIV-infected indi-viduals. In: Program and abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy; September 1998; San Diego. Abstract 1–75.
   Google Scholar
• Bartlett J, DeMasi R, Quinn J, Moxham C, Rosseau F. Correlation between antiretroviral pill burden and durability of virologic response; a systematic review. In: Program and abstracts of the 13th International AIDS Conference; July 2000; Durban, South Africa. Abstract ThPeB4998.
   Google Scholar
• Montessori V, Heath KV, Yip B, Hoggs RS, et al. Predictors of adherence with triple combination antiretroviral therapy. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; February 2000; San Francisco. Abstract 72.
   Google Scholar
• Murri R, Ammassari A, De Luca A, et al. Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clin Trials. 2001;2(4):323–329.
   PubMedGoogle Scholar
• Ammassari A, Antinori A, Pezzotti P, et al. Relationship of depression, neurocognitive impairment and HAART adher-ence. In: Program and abstracts of the 8th European Con-ference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens. Abstract P–79.
   Google Scholar
• Bangsberg DR, Perry S, Charlebois ED, et al. Depression symptoms predict HAART adherence, duration, unstruc-tured treatment interruption and viral suppression. In: Pro-gram and abstracts of the International Conference on Antimicrobial Agents and Chemotherapy; December 2001; Chicago. Abstract 1–1721.
   Google Scholar
• Department of Health and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: www.hivatis.org. Last accessed January 2002.
   Google Scholar
• Rachlis A, Becker S, Gill J, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - a prospective, randomized, multicenter, open-label study (DMP 049). In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires. Abstract 418.
   Google Scholar
• Paes A, Bakker A, Soe-Agnie J. Impact of dosage fre-quency on patient compliance. Diabetes Care. 1997;20:1512–1517.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Verdon, Bazin C. Once-daily regimen may in-crease drug holidays. J Infect Dis. 2001183:1539.
   Google Scholar
• Molina JM, Ferchal F, Rancinan C, et al. Once daily therapy with emitricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599–602.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivi-ral Ther. 2002;6:249–253.
   Web of Science ®Google Scholar